<DOC>
	<DOCNO>NCT02623764</DOCNO>
	<brief_summary>Drug treatment cholinesterase inhibitor indicate treatment Alzheimer´s disease case , one drug prescribe soon diagnosis make . Nevertheless , show several study 30 % patient benefit treatment . These drug side effect , frequently gastrointestinal tract nausea , diarrhea discomfort abdomen frequent sign . It therefore important know treatment initiate patient likely benefit drug . It possible today current knowledge project aim evaluate specific index , calculate EEG registration ( EEG-cholinergic index ) purpose . A conventional EEG registration do treatment cholinergic index calculate EEG registration compare clinical outcome . The duration follow 6 month extension 6 month .</brief_summary>
	<brief_title>EEG-cholinergic Index Clinical Response Treatment With Cholinesterase Inhibitors</brief_title>
	<detailed_description>Patients recruit Memory Clinic . Three possible group participant offer participation : - Those Mild Cognitive Impairment ( MCI ) biomarkers Alzheimer´s disease ( AD ) conclusive enough lead diagnosis AD initiate medical treatment . - Those early dementia AD offer medical treatment able give consent . - Those early dementia Lewy body dementia Parkinson dementia offer medical treatment . All eligible participant evaluate Mini Mental State Examination ( MMSE ) , Consortium Establish Registry Alzheimer´s Disease ( CERAD 10 word test ; work memory , delayed memory recognition ) Clock Drawing Test ( CDT ) . In addition , Addenbrooke test use . Patients AD irrespective stage offer treatment donepezil , use cheap cholinesterase inhibitor Iceland . The dosis usual , 5mg even four week , increase 10mg evening . Patients Lewy body dementia Parkinson dementia offer rivastigmine patch medication indication cognitive impairment disorder . The start dose 4.6mg/day increase 9.5mg/day 4 week . After 3 month , participant evaluate test initiate treatment ( continuous variable ) . The clinical effect also rat accord Clinical Dementia Rating ( CDR ; categorical variable ) . An EEG registration perform . Adherence drug therapy well evaluation side effect registrated . After 6 month , participant evaluate 3 month . This primary end point . After 12 month additional evaluation perform instrument ( secondary endpoint ) . The EEG thus registrated 3 time ( primary end point ) 4 time ( secondary end point first registration do diagnostic work enter project . The EEG reveal group wise category ( Normal , AD Lewy accord third edition ( SIGLA ) Mentis Cura ) . An analysis cholinergic index reveal clinician thus blind part EEG analysis . The project analyse base available information primary end point . A second analysis perform second end point .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cholinesterase Inhibitors</mesh_term>
	<mesh_term>Cholinergic Agents</mesh_term>
	<criteria>Mild Cognitive Impairment mild dementia due Alzheimer´s disease dementia due Lewy body disease . Too advanced dementia ( 5 Global Deterioration Scale ) likelihood poor compliance due social circumstance , drug alcohol abuse define cause .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Alzheimer´s disease</keyword>
	<keyword>Lewy body dementia</keyword>
	<keyword>Parkinson dementia</keyword>
	<keyword>EEG</keyword>
	<keyword>Cholinergic index</keyword>
</DOC>